Kayla K. Lemmon
YOU?
Author Swipe
View article: A Novel Playbook for Pragmatic Trial Operations to Monitor and Evaluate Ambient Artificial Intelligence in Clinical Practice
A Novel Playbook for Pragmatic Trial Operations to Monitor and Evaluate Ambient Artificial Intelligence in Clinical Practice Open
We provide a publicly available framework and protocols to help safely implement ambient AI in health care. Innovations include an embedded pragmatic trial design, human factors engineering, compliance-driven feedback loops, and real-time …
View article: Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity
Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity Open
Tumor heterogeneity is predicted to confer inferior clinical outcomes with precision-based strategies, however, modeling heterogeneity in a manner that still represents the tumor of origin remains a formidable challenge. Sequencing technol…
View article: Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only…
View article: Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Figure S1 presents the viability of SW48 and SW48PK cells after treatment with BEZ235 and TAK-228 at the 100-400nM concentrations.
View article: Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Table S1 compares the intestinal tumor counts and percent of tumors progressing to cancer for mouse models with activating alterations in PIK3CA.
View article: Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Data from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only…
View article: Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Table S1 compares the intestinal tumor counts and percent of tumors progressing to cancer for mouse models with activating alterations in PIK3CA.
View article: Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
Supplementary Figure S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
Supplementary Figure S1 presents the viability of SW48 and SW48PK cells after treatment with BEZ235 and TAK-228 at the 100-400nM concentrations.
View article: Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Stock culture and feeding media.
View article: Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Dot plots corresponding to population distribution curves and graphs of individual replicates for bar graphs in Figure 4.
View article: Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5B.
View article: Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Stock culture and feeding media.
View article: Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Purpose:Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predicts…
View article: Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Detailed characteristics of CRC PDOCS.
View article: Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Supplementary Methods
View article: Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S2 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5B.
View article: Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5E.
View article: Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Detailed characteristics of CRC PDOCS.
View article: Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Supplementary Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Supplementary Methods
View article: Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
(A) Individual replicates of data shown in Figure 6A. (B) Individual replicates of data from Figure 6D.
View article: Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S3 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Individual replicates for data shown in Figure 5E.
View article: Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Dot plots corresponding to population distribution curves and graphs of individual replicates for bar graphs in Figure 4.
View article: Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Success rates for growing human cancers in spheroid culture
View article: Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Table S1 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Success rates for growing human cancers in spheroid culture
View article: Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Data from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Purpose:Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predicts…
View article: Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Figure S4 from Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
(A) Individual replicates of data shown in Figure 6A. (B) Individual replicates of data from Figure 6D.
View article: Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity
Integrating Subclonal Response Heterogeneity to Define Cancer Organoid Therapeutic Sensitivity Open
Tumor heterogeneity is predicted to confer inferior clinical outcomes, however modeling heterogeneity in a manner that still represents the tumor of origin remains a formidable challenge. Sequencing technologies are limited in their abilit…
View article: Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation Open
Purpose: Cancer treatment is limited by inaccurate predictors of patient-specific therapeutic response. Therefore, some patients are exposed to unnecessary side effects and delays in starting effective therapy. A clinical tool that predict…
View article: MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers
MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers Open
PIK3CA mutations are common in clinical molecular profiling, yet an effective means to target these cancers has yet to be developed. MTORC1 inhibitors are often used off-label for patients with PIK3CA mutant cancers with only limited data …